STOCKS TELEGRAPH

Tag: MURAL

  • Mural Oncology (MURA) Shares Skyrocket Amid Major Corporate Shift

    Mural Oncology (MURA) Shares Skyrocket Amid Major Corporate Shift

    Following the announcement of its intention to investigate strategic alternatives, Mural Oncology plc (NASDAQ: MURA) is seeing a sharp increase in share value. MURA stock surged to $2.65 as of the most recent check today, representing a remarkable 157.27% rise. The dramatic increase comes after the company decided to stop clinical development of nemvaleukin alfa, its main experimental treatment.

    Clinical Trials Produce Unsatisfactory Findings

    Following a comprehensive analysis of the data from its ongoing clinical trial, ARTISTRY, Mural Oncology came to this decision. Specifically, in cohort 2 of the phase 2 ARTISTRY-6 research, which looked at nemvaleukin alfa’s efficacy as a monotherapy in 92 patients with mucosal melanoma, it failed to meet its main objective.

    Additionally, preliminary results from cohort 3, which assessed less frequent intravenous dosing in cutaneous melanoma patients, also showed insufficient activity to support additional research.

    These findings are in line with the interim overall survival data for platinum-resistant ovarian cancer from the phase 3 ARTISTRY-7 study, which were published on March 25, 2025. Mural Oncology has decided to cease further nemvaleukin alfa clinical research in light of these findings.

    Strategic Alternatives and Workforce Reductions

    As a result, MURA has started a formal procedure to investigate strategic options with the goal of increasing shareholder value. Mergers, acquisitions, company combinations, and other corporate transactions are examples of possible routes being examined.

    Mural Oncology has chosen Lucid Capital Markets, LLC to serve as its financial adviser in order to facilitate this process. About 90% of MURA’s personnel will be impacted by the company’s planned drastic workforce reduction as part of its restructuring initiatives.

    Future Outlook and Disclosures

    Despite the strategic assessment, Mural Oncology issued a warning: neither the terms nor the type of a possible acquisition are guaranteed, nor is there any certainty that a transaction would be finalized. Additionally, MURA stated that it has not received any takeover bids and is not now in contact with any potential offerors. As required by regulatory requirements, updates will be sent.

  • Is It Right Time To Buy Zoom Video Communications (NASDAQ: ZM) Stock?

    Is It Right Time To Buy Zoom Video Communications (NASDAQ: ZM) Stock?

    Zoom Video Communications, Inc. (NASDAQ: ZM) has gained +27.15 during the trading session of Thursday. The strong performance of the company indicated the positive sentiments of investors after a bullish call from Bernstein. Including Bernstein, nine analysts have lifted their price targets after the conference.

    This strong sentiments by investors are because of the Zoom’s investors conference in which the company announces the plan to launch new features, including end-to-end encryption. The company has revealed that its platform is getting third-party app integration called Zapps. Moreover, it has also announced the OnZoom platform which will provide an opportunity to users who wants to host free and paid virtual events.

    This is not the end the now-ubiquitous technology company has also announced a new software Kit (SDK) which will be customizable. This new kit will provide an opportunity for developers to create a customs app for the platform. Furthermore, Zoom has also announced some minor customization options for the core videoconference service like immersive scenes and a smart gallery for Zoom Rooms.

    Zoom Video Communications, Inc. (NASDAQ: ZM) shares were trading up 5.33% at $536.40 at the time of writing on Thursday. Zoom Video Communications share price went from a low point around $60.97 to briefly over $529.74 in past 52 weeks, though shares have since pulled back to $536.40. ZM market cap has remained high, hitting $148.27 Billion at the time of writing.

    Bernstein’s new price target nearly doubled the earlier price and the new price target is $611 from $228. Likewise, Needham has also raised the price target from $440 to $540 and RBC Capital Mkts has set the new price target of $600 from $450. BTIG maintained a buy rating and raised the price target to $500.

    The other five remaining investors who raise the price target for Zoom shares include BofA Securities as it maintained a buy rating and raised the price target from $475 to $570. Rosenblatt has maintained its neutral rating and lifted the price target from $350 to $450. Wells Fargo has maintained an equal-weight rating, ups price target from $375 to $465. DA Davidson has maintained a buy rating, boost the price target from $460 to $600 and Stifel Nicolaus maintained a hold rating, lifted the price target from $350 to $400.

    Previously, MURAL has announced that it has included Zoom Video communication in its growing network of collaboration platform partners. After this partnership, Zoom participants will be able to collaborate in the facilitator’s MURAL, even if they are not a MURAL customer.